secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2022-12-21T23:59:59+00:00
Accession:  0001558370-22-018894
Event type: other
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix BioTherapeutics voluntarily delists from Tel Aviv Stock Exchange; NYSE American listing unaffected
--------------------------------------------------------------------------------

- Company requested immediate delisting of common stock from TASE; effective three months from request.
- Stock continues trading on TASE during the three-month period; all shares expected to transfer to NYSE American.
- NYSE American listing and SEC reporting obligations remain unchanged; company will focus on U.S. capital market.
- Decision aims to reduce operating costs by having a single set of listing rules and regulations.
- No financial impact disclosed; delisting is voluntary and procedural.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837022018894/0001558370-22-018894-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837022018894/plx-20221221x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-018894

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer